Communications for Statistical Applications and Methods

The Korean Statistical Society (한국통계학회)
권호 표지
DOI QR코드

DOI QR Code

Detecting an Outlier in 2X2 Bioequivalence Trial

2X2 생물학적 동등성 시험에서 이상치 검출을 위한 통계적 방법

  • 정규진 (한남대학교 비즈니스 통계학과) ;
  • 박상규 (중앙대학교 수학통계학부) ;
  • 우화형 (중앙대학교 수학통계학부)
  • Published : 2009.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Outlying or extreme observations are defined to be subject data for which one or more bioavailability measures are discordant with corresponding data for that subject and/or for the rest of the subjects in a study. The presence of outlying observations can have very serious consequences on the conclusions resulting from a bioequivalence study. Two statistical methods are proposed by generalizing the current well known methods and an illustrated example is presented with discussion.

생물학적 동등성 시험에서 피험자로부터 얻어진 생체 이용률 자료들 중 하나 혹은 일부가 다른 자료에 비해 크게 차이가 나는 자료를 이상치라 정의한다. 이러한 이상치의 존재는 소수의 피험자로 이루어지는 생물학적 동등성 시험의 결과에 큰 영향을 주는 것으로 알려져 있다. 생물학적 생동성 시험에서 이상치를 판별하는 통계적 방법 중 우도거리 혹은 추정량거리를 비교하는 통계적 검정이 많이 활용되고 있는데 본 연구논문에서는 이러한 통계적 방법을 보다 일반화하여 이상치를 판단하는데 보다 효율적인 검정 방법을 제안한다. 제안된 방법은 예제를 통해 자세하게 논의된다.

Keywords

References

  1. 식품의약품안전청 (2008). 생물학적동등성시험기준(제2008-22호)
  2. Bolton, S. (1991). Outliers-Examples and Opinions, Presented at Bioavailability / Bioequivalence: Phar-macokinetic and Statistical Considerations sponsored by Drug Information Association, Bethesda, Maryland
  3. Chow, S. C. and Liu, J. P. (2009). Design and Analysis of Bioavailability and Bioequivalence Studies, 3rd Ed., Chapman & Hall/CRC, Florida
  4. Chow, S. C. and Tse, S. K. (1990). Outlier detection in bioavailability / bioequivalence studies, Statistics in Medicine, 9, 549-558 https://doi.org/10.1002/sim.4780090508
  5. Clayton, D. and Leslie, A. (1981). The bioavailability of erythromycin stearate versus enteric-coated ery-thromycin base when taken immediately before and after food, Journal of International Medical Re-search, 9, 470-477 https://doi.org/10.1177/030006058100900608
  6. FDA (2000). Guideline for Industry: Bioavailability and Bioequivalence Studies for Orally Adminis-tered Drug Products? General Considerations, Rockville. Maryland: Center for Drug Evaluation Research, Food and Drug Administration
  7. Ki, F. Y. C., Liu, J. P., Wang, W. and Chow, S. C. (1995). The impact of outlying subjects on decision of bioequivalence, Journal of Biopharmaceutical Statistics, 5, 71-94 https://doi.org/10.1080/10543409508835099
  8. Liu, J. P. and Weng, C. S. (1991). Detection of outlying data in bioavailability / bioequivalence studies, Statistics in Medicine, 10, 1375-1389 https://doi.org/10.1002/sim.4780100906
  9. Metzler, C. M. and Huang, D. C. (1983). Statistical methods for bioavailability and bioequivalence, Clini-cal Research Practices and Drug Regulatory Affairs, 1, 109-132 https://doi.org/10.3109/10601338309024010
  10. Ramsay, T. and Elkum, N. (2005). A comparison of four different methods for outlier detection in bioe-quivalence studies, Journal of Biopharmaceutical Statistics, 15, 43-52 https://doi.org/10.1081/BIP-200040815
  11. Rodda, B. E. (1986). Bioequivalence of Solid Oral Dosage Forms, A presentation to the U. S. Food and Drug Administration Hearing on Bioequivalence of Solid Oral Dosage Forms, September 29-October 1, Pharmaceutical Manufacturers Association, Section Ⅲ, 12-15
  12. Wang, W. and Chow, S. C. (2003). Examining outlying subjects and outlying records in bioequivalence trials, Journal of Biopharmaceutical Statistics, 13, 43-56 https://doi.org/10.1081/BIP-120017725

Cited by

  1. On Evaluation of Bioequivalence for Highly Variable Drugs vol.24, pp.6, 2011, https://doi.org/10.5351/KJAS.2011.24.6.1055